Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
AstraZeneca
Johnson and Johnson
Baxter
Merck

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GBT440

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug GBT440?

GBT440 is an investigational drug.

There have been 16 clinical trials for GBT440. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2016.

The most common disease conditions in clinical trials are Anemia, Sickle Cell, Pulmonary Fibrosis, and Idiopathic Pulmonary Fibrosis. The leading clinical trial sponsors are Global Blood Therapeutics, National Heart, Lung, and Blood Institute (NHLBI), and Mayo Clinic.

There are ten US patents protecting this investigational drug and one hundred and seventy international patents.

Recent Clinical Trials for GBT440
TitleSponsorPhase
Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell DiseaseGlobal Blood TherapeuticsPhase 3
Pediatric Open-Label Extension of VoxelotorGlobal Blood TherapeuticsPhase 3
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects With Stable Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI)Phase 1

See all GBT440 clinical trials

Clinical Trial Summary for GBT440

Top disease conditions for GBT440
Top clinical trial sponsors for GBT440

See all GBT440 clinical trials

US Patents for GBT440

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GBT440   Start Trial Methods of treatment Global Blood Therapeutics, Inc. (South San Francisco, CA)   Start Trial
GBT440   Start Trial Compounds and uses thereof for the modulation of hemoglobin Global Blood Therapeutics, Inc. (South San Francisco, CA)   Start Trial
GBT440   Start Trial Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation Global Blood Therapeutics, Inc. (South San Francisco, CA)   Start Trial
GBT440   Start Trial Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzal- dehyde Global Blood Therapeutics, Inc. (South San Francisco, CA)   Start Trial
GBT440   Start Trial Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde Global Blood Therapeutics, Inc. (South San Francisco, CA)   Start Trial
GBT440   Start Trial Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation Global Blood Therapeutics, Inc. (South San Francisco, CA) Cytokinetics, Inc. (South San Francisco, CA) The Regents of the University of California (Oakland, CA)   Start Trial
GBT440   Start Trial 1:1 adducts of sickle hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GBT440

Drugname Country Document Number Estimated Expiration Related US Patent
GBT440 Australia 2016243428 2035-03-30   Start Trial
GBT440 Brazil 112017020276 2035-03-30   Start Trial
GBT440 Canada 2980578 2035-03-30   Start Trial
GBT440 Chile 2017002435 2035-03-30   Start Trial
GBT440 China 107531671 2035-03-30   Start Trial
GBT440 Eurasian Patent Organization 201791998 2035-03-30   Start Trial
GBT440 European Patent Office 3277379 2035-03-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Boehringer Ingelheim
Moodys
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.